ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2515

Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases

Shinji Izuka1, Toshihiko Komai1, Takahiro Itamiya1, Mineto Ota2, Saeko Yamada1, Yasuo Nagafuchi2, Hirofumi Shoda1, Kosuke Matsuki3, Kazuhiko Yamamoto4, Tomohisa Okamura5 and Keishi Fujio1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Bioinformatics, Myositis, Systemic lupus erythematosus (SLE), Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc). Despite its unique clinical characteristics, some patients may develop other rheumatic diseases during a follow-up period [1]. To better understand the heterogeneity of MCTD and to stratify the patients, we developed machine learning models using immunophenotyping as a reference for SLE, idiopathic inflammatory myopathy (IIM), and SSc and identify differences in symptoms and transcriptome among the subgroups of MCTD.

Methods: We employed our large-scale database, Immune Cell Gene Expression Atlas from the University of Tokyo (ImmuNexUT) [2], to analyze the immunophenotyping (24 subsets) of patients with MCTD alongside SLE, IIM, and SSc. By utilizing the immunophenotyping data of SLE, IIM, and SSc, we developed machine learning models such as random forest, neural network, etc., to stratify MCTD patients. Following the stratification of the MCTD patients, we performed a transcriptome analysis, including a differentially expressed gene (DEG) analysis and pathway analysis. Finally, we compared the clinical features of the subgroup of MCTD patients (Figure 1).

Results: We enrolled a total of 215 patients with autoimmune diseases, consisting of 22 MCTD, 78 SLE, 63 IIM, and 52 SSc patients, and collected the data of immunophenotyping, bulk RNA-sequence on peripheral mononuclear blood cells, and clinical characteristics. We constructed machine learning models to classify patients with SLE, IIM, and SSc based on the immunophenotyping and applied these models to the MCTD patients. Of the 22 patients with MCTD, 16 were classified as SLE-phenotype, and 6 were classified as non-SLE-phenotype (4 IIM-phenotype and 2 SSc-phenotype). Among the MCTD patients, SLE-phenotype patients had significantly higher proportions of Th1, naïve B cells, and plasmablast (p=0.03, 0.01, and 0.01, respectively) (Figure 2). Regarding clinical features, the proportions of having the SLE symptoms such as lymphadenopathy, malar rash, serositis, and cytopenia were significantly higher in SLE-phenotype patients (87.5% vs 33.3%, p=0.025). The number of DEGs across the cell types between SLE patients and MCTD patients (SLE-phenotype and non-SLE-phenotype) was comparable.

Conclusion: Our study suggested the potential stratification of MCTD patients based on their immunophenotyping. This approach may help distinguish clinical phenotypes in MCTD.

[1] Reiseter S et al, Arthritis Res Ther 2017
[2] Ota M et al, Cell 2022

Supporting image 1

Figure 1. Workflow of this study

Supporting image 2

Figure 2. Comparison of immunophenotyping and clinical features of MCTD patients between SLE-phenotype and non-SLE-phenotype patients.


Disclosures: S. Izuka: Eisai, 6; T. Komai: Amgen, 6, Asahi Kasei, 6, Chugai, 5, 6, Daiichi-Sankyo, 6, Eisai, 6, Eli Lilly, 1, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 6, Novartis, 6, Tanabe Mitsubishi, 6; T. Itamiya: Chugai Pharmaceutical Co., Ltd., 5; M. Ota: Chugai Pharmaceutical., 12, belong to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical.; S. Yamada: Asahi Kasei, 6, Chugai Pharmaceutical., 6, Pfizer, 6; Y. Nagafuchi: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai Pharmaceutical., 12, belong to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical., GlaxoSmithKlein(GSK), 5, Novartis, 6; H. Shoda: AbbVie/Abbott, 6, Asahi Kasei, 6, Astellas, 6, AstraZeneca, 6, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 6, Chugai Pharmaceutical., 6, Daiichi-Sankyo, 6, Eisai, 6, Eli Lilly, 6, Gilead, 6, GlaxoSmithKline, 6, Jansen, 6, Novartis, 6, Pfizer, 6, Sanofi, 6, Taisho Pharmaceutical, 6, Takeda, 6; K. Matsuki: Chugai Pharmaceutical., 3; K. Yamamoto: AbbVie, 6, Pfizer Japan Inc, 12, Outsourcing contract, RegCell, 1, Sun Pharmaceutical Industries Ltd, 6; T. Okamura: Chugai Pharmaceutical., 12, belong to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, supported by Chugai Pharmaceutical.; K. Fujio: AbbVie/Abbott, 6, Asahi Kasei, 5, 6, Astellas, 6, AstraZeneca, 6, Ayumi, 6, Bristol-Myers Squibb(BMS), 5, 6, Chugai Pharmaceutical., 5, 6, Daiichi-Sankyo, 6, Eisai, 5, 6, Eli Lilly, 5, 6, Janssen, 6, Novartis, 6, Ono, 6, Pfizer, 6, Sanofi, 6, Tanabe Mitsubishi, 5, 6, Tsumura, 5.

To cite this abstract in AMA style:

Izuka S, Komai T, Itamiya T, Ota M, Yamada S, Nagafuchi Y, Shoda H, Matsuki K, Yamamoto K, Okamura T, Fujio K. Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/machine-learning-based-stratification-of-mixed-connective-tissue-disease-using-immunophenotyping-data-from-patients-with-related-autoimmune-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/machine-learning-based-stratification-of-mixed-connective-tissue-disease-using-immunophenotyping-data-from-patients-with-related-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology